Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Brett Linzey
Period: Reporting periods mapped to calendar 2024 Q4 – 2026 Q2 (7 quarters).
- Questions
- 72on tracked calls
- Challenge rate
- 4%3 of 72 questions
- Companies
- 11questioned at least once
- Reporting periods
- 7with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 72 of 72 questions from 11 companies
IEXIDEX Corporation11 questions · 6 reporting periods · 0 of 11 challenging
Calendar 2026 Q2
should we begin to see the incremental margins drive higher above where they would normally in an inflection
Show response
Gave the clean ex-IEEPA flow-through and guided to that level persisting, attributing the step-up to accretive gross margin mix from acquired businesses.
the rebates that are tied to the IEEPA refunds, how do we think about the allocation of that?
Show response
Explained rebate allocation depends on original customer pricing arrangements and stated the refund and rebate activity is essentially confined to Q2.
Calendar 2026 Q1
The stable Europe comment, I think, is maybe a change in trend
Show response
CEO recalled European fire and safety turned down unexpectedly late summer last year due to alternate spending priorities. Came back to normal corridor by year-end and remained there. Not widely growing but back in normal range. Temporal shift rather than structural. Further-from-home markets stable. Growth strength concentrated in North America.
how are those performing versus the more OpEx-oriented businesses?
Show response
CFO emphasized no material shift in CapEx intensity; increase is in line with growth and angled toward HST. CEO added low capitalization requirements are part of the filter set for technology and acquisitions. Gives agility and optionality to move technology fast. CapEx rising simply because growth rates are rising.
Calendar 2025 Q3
how should we think about any carryover into next year? And then how much would be maybe structural versus discretionary
Show response
Interim CFO split savings into two buckets: $42M platform optimization and delayering is structural and at run rate this quarter. $20M cost containment is temporal and could come back depending on investment opportunities. Total $62M for full year.
Calendar 2025 Q2
I know IDEX exposure isn't huge there, but you do have some larger landed exposure indirectly into China and HST
Show response
CEO confirmed China about 6% of revenue with pressure in HST customer exports, direct shipping, and rescue business. India more than offsetting China weakness. Asia Pac concentration surgical between China and India.
you're moving from the $100 million to the $50 million. Could you just expand a bit on some of the underlying assumptions there
Show response
Interim CFO confirmed $50M excludes copper tariffs, finalized Europe/Japan rules, and any Taiwan/China changes from status quo. Will continue to offset incremental tariffs one for one with price.
Calendar 2025 Q1
are you seeing any spending reductions or impact on grants driving customer spending decisions at this point
Show response
CEO said NIH funding impact low percentage for customers and read-through even lower. Life science pharma strength offsets genomics government funding risk. Defense and space spending strength provides additional offset.
Is it fair to say price is up and you are taking a little bit more hedge on the volume side
Show response
CFO confirmed: original 1.5pt price now 3pt with incremental tariff pricing. Volume range shifted to down 2% at low end and flat at high end. $20M cost out protects against 3-4% back-half volume decline.
Calendar 2024 Q4
you indicated that the challenging comparable in life science and analytical as an offset to strength elsewhere
Show response
CFO clarified life sciences sales have been sequentially flat across all four 2024 quarters but still down year-over-year versus 2023 levels.
Can you just clarify within that $0.15 to $0.40 that's organic, how much are you embedding for price cost
Show response
CFO confirmed 60-80bps price-cost spread for the full year. Incremental $10M pricing in H2 due to Q1 lag from annual price increase announcements. No negative position at any point.
HUBBHubbell Incorporated10 questions · 5 reporting periods · 0 of 10 challenging
Calendar 2026 Q2
the net $20 million in Q3, sounds like that is all refund. what is implied for Q4 in terms of the refund impact
Show response
Capozzoli confirmed the refund is fully in Q3 and characterized the Section 301 framework changes as minor pluses and minuses.
How are you thinking about the, you know, the progression and the ability to get back to the 100% plus
Show response
Capozzoli pushed back on a near-term return to 100%, guiding to roughly 90% conversion for the next couple of years on elevated CapEx and working capital.
Calendar 2025 Q4
How do we think about those markets in the context of the mega project momentum you noted in the prepared remarks?
Show response
Mega projects and reshoring activity flowing through light industrial rather than nonres/heavy industrial markets. No tangible signs of meaningful acceleration in nonres or heavy industrial. Will update if trajectory changes.
should we think of the associated savings as maybe some cushion as those paybacks convert through the year?
Show response
Restructuring investments are self-funding with prior-year actions paying back while current $15-20M investment has 2-3 year payback horizon. Creates ongoing momentum of savings. Attractive R&R opportunity pipeline remains ahead.
Calendar 2025 Q2
can you sustain that double-digit growth range into next year based on your current visibility in those businesses?
Show response
Core portfolio strength in T&S with strong specifications and relationships. Won some of largest US transmission projects. Multiyear visibility supports Investor Day high-single-digit growth framework.
is it mostly just the MRO side? Or are you beginning to see some RFPs start to ramp back up on new projects that could be slated for next year?
Show response
Current stability driven by MRO and smaller projects focused on public power (co-ops, munis). Some larger project RFPs in pipeline being quoted but timing and win rate uncertain.
Calendar 2025 Q1
how did that track versus the internal expectation and then implicitly, the utility meters business was down much more than that
Show response
Grid automation softer than expected but offset by stronger T&D performance. Meters/AMI outlook more modest with smaller projects and MRO creating a floor.
are there any other indicators or anecdotes from large utilities or inventory data from distributors that gives you more confidence
Show response
Distributor and end customer dialogues confirm inventories much more in line with targets. May be isolated SKU/geography pockets but overall destocking period is over.
Calendar 2024 Q4
Certainly, a bigger figure relative to last year, able to parse out that between growth and productivity?
Show response
Investment paybacks are attractive with growth projects having slightly better returns than productivity ones, which pay back in approximately three years. More projects on the board than will be executed.
Can you frame the size of the exit backlog in terms of months or weeks?
Show response
Q1 meters/AMI expected to look similar to Q4, with improvement through the balance of 2025 as backlog needs to be rebuilt through incoming RFPs and orders.
LIILennox International10 questions · 6 reporting periods · 0 of 10 challenging
Calendar 2026 Q2
When do you think those deferred cost-out initiatives resume? And are they volume-dependent
Show response
Alok said the deferral is mostly timing from shifting engineering resources to tariff mitigation, and expects full recapture next year if tariff rules stabilize.
historically, you know, ER was above segment margins. Where are we in that ramp process?
Show response
Alok placed emergency replacement margins in line with large national accounts with room to expand; Michael corrected the premise that they were above segment average.
Calendar 2025 Q4
Did you actually see positive parts growth in the fourth quarter? And then are there any regional or efficiency level observations
Show response
CEO confirmed parts grew more than equipment through most of 2025, supported by both HARDI data and internal data. No specific regional differences in trade-down patterns observed.
an update on how NSI is now tracking organically and pulled in the And then as you continue to build out that parts pull-through strategy
Show response
CEO said acquisition tracking as expected with only two months of data. 2026 focused on integration with ERP conversion costs. CFO noted legacy parts business at $500M with HCS attachment only at 15% versus 20-25% target, highlighting significant runway.
Calendar 2025 Q3
drill down on the magnitude and the scope of the consumer trade down. I guess in the context of regional variances
Show response
CEO noted trade-down more visible in Northeast versus Southern states where AC is essential. Confirmed repair trend through increased spare parts and coil sales data. Expects reversal in 2026 as canister availability normalizes and contractor confidence returns.
you also do have potentially some load in from NSI. As you move through the one-step. So hoping you could maybe frame some of those moving pieces
Show response
CEO expects good free cash flow conversion in 2026. Durodyne/Subco (referred to as NSI) comes with healthy inventory levels and should convert at a high level. Biggest tailwind will be the finished goods inventory reduction.
Calendar 2025 Q2
is there any data you can share on the rate of growth in the parts categories versus equipment or something fundamental in the second quarter driving that sentiment
Show response
CEO noted Lennox is underweight in parts so wouldn't see a repair-vs-replace uptick in its own data. Parts sales were normal in Q2. The repair-vs-replace observation is based on dealer conversations and industry trends, not numerical evidence.
as that capacity gets stood up and you're back in the emergency replacement market, do you have any updated thinking on factory output
Show response
CEO expressed satisfaction at pivoting from inefficiency to productivity discussion. Saltillo focused on standard emergency replacement units, Stuttgart on configured products. Labor force scaled back through attrition. Productivity run expected to continue multiple quarters.
Calendar 2025 Q1
Was this solely product availability or are you seeing some price sensitivity on the new products and the price uptake there
Show response
CEO confirmed delays were driven by technician training, tool upgrades, and key accounts finishing 410A jobs, not product availability or price sensitivity. Described it as a short-term air pocket.
Calendar 2024 Q4
Are you able to quantify what you're embedding in 2025 in terms of the volume contribution and better throughput there
Show response
CFO confirmed a few points of the mid-single digit BCS volume growth are share gains from new factory capacity, predominantly in the second half starting late Q2.
ALLEAllegion8 questions · 4 reporting periods · 0 of 8 challenging
Calendar 2025 Q4
Maybe just talk about the pricing capture you expect this year on a net basis and what you're calibrating within the guidance framework?
Show response
Mike confirmed 2026 will be more list price vs surcharges. Lower total inflation assumption means lower total pricing. More pricing than volume in organic growth.
The $9 million tailwind in 4Q within Americas, is that just a function of the timing of some projects and some spending?
Show response
Mike framed investments within full PPII context, quarter-to-quarter can move around but full year pricing+productivity must fund inflation+investment. Q1 tough comp then normalizes.
Calendar 2025 Q2
how did that compare relative to the original expectation on a netting basis? Were there any surcharge rollbacks you had to do on the deescalation
Show response
Mike confirmed surcharges were adjusted as government changed tariff policy. Flexible approach. Enterprise PPII expected breakeven to slightly positive for full year.
your long-term framework target the 3 points of annual acquired growth, certainly running ahead here
Show response
John noted several deals closed in tight window but pipeline remains active. ELATEC was long-targeted. Integration muscle accelerating.
Calendar 2025 Q1
Has all the price you need to offset the $80 million now been announced with this this second April round of price
Show response
Mike confirmed pricing actions announced in April cover currently enacted tariffs. Additional tariff changes would prompt additional actions.
what does the composition between those two pricing levers look like? And then I guess at what point do you just assume the tariffs are maybe structural
Show response
John confirmed surcharges used given tariff volatility. Conversion to list price depends on whether tariffs become structural. Remaining agile.
Calendar 2024 Q4
How are you thinking about commercial versus institutional? Do you see growth in both of those areas?
Show response
Institutional supported by muni bonds, data centers growing fast, commercial office/multifamily still soft but nearing bottom. Phasing similar to 2024.
what would the mechanics of price look like? Would these be normal list prices or would they be surcharges
Show response
John declined to speculate on specific pricing mechanics for hypothetical Mexico tariffs but confirmed intent to offset at OI/EPS level.
AMEAmetek8 questions · 4 reporting periods · 0 of 8 challenging
Calendar 2025 Q4
Any any signs of prebuy or prebuild in in some of those channels
Show response
No signs of prebuy or restock. Environment feels more normalized entering 2026 vs 2025 when buy-ahead dynamics were present. Demand patterns returning to normal cadence.
Maybe discuss your your actual pricing expectation for 2026. And then how are you thinking about price cost spread for the year?
Show response
Q4 price offset inflation + tariffs + ~50bp positive spread. Expect similar performance in 2026. Not giving specific price target but strong history of positive price-cost spread due to differentiated product portfolio and niche market leadership.
Calendar 2025 Q2
how much of that did ship in 2Q? And are you assuming that the remaining gets delivered as part of the framework?
Show response
Good majority of $70M shipped in Q2. Remainder expected to resolve in Q3/Q4. Did not quantify exact split.
are customers giving you any sense on the timing of that quotation activity and what the budgeting time line might look like there
Show response
Uncertainty more about tariff direction than level. As trade deals conclude, cloud lifts from project decisions. Tax bill and reshoring provide positive offsets.
Calendar 2025 Q1
Perhaps just an update on the level of OEM inventory in some of those channels. And then anything in terms of the pulse on capital projects?
Show response
Process business outlook adjusted down due to project delays. OEM destocking nearing end: U.S. automation largely finished, Europe (Germany) still working through.
How are those businesses performing versus expectations? And is your thinking and outlook changed between commercial and defense
Show response
A&D on track with balanced commercial and defense growth. OEM backlogs 8-10 years. Aftermarket benefiting from slower fleet retirements and older planes flying longer.
Calendar 2024 Q4
could you give us an update on how you're thinking about the outlook on aero versus defense? I know a lot of moving pieces there
Show response
A&D up mid-single digits in Q4 with commercial stronger. 2025 outlook mid-single digits with both commercial and defense healthy. No margin concern on OE vs aftermarket shift.
Are customers giving you any indication on the timing of when these projects might release? And how are you thinking about ES, Engineered Solutions
Show response
Management expects delayed projects to convert in 2025, automation business has bottomed, and med tech destocking already abating.
PNRPentair7 questions · 4 reporting periods · 1 of 7 challenging
Calendar 2026 Q2
What is the jumping off point from here? Is there any, you know, kind of onetime noise, or is it a sustainable run-rate
Show response
Fishman said both segments can keep expanding return on sales via sourcing and complexity reduction, but gave no quantified ex-tariff jumping-off point.
Are there any other, signals or KPIs that are giving you a little bit more confidence that things do, in fact, come back
Show response
Stauch explained channel inventory unwinds at a 2x factor and will be cleared by Q3, with moderating 2027 price removing the prebuy incentive.
Calendar 2025 Q4
Expect to deliver the $70 million in '26, and you're implementing this wave three, maybe just talk about the phasing of that as you progress through 2026
Show response
CEO confirmed another $70M net transformation year (net of headwinds and investments). Investments front-loaded, so contribution skewed to Q2-Q4. Most already in funnel to be realized vs. created.
Does the $14 million include tariff plus some assumption for just general inflation of metals?
Show response
CEO clarified the $14M is tariff-only. General metal inflation captured separately. Pricing to channel covers both tariffs and normalized wage/general inflation.
Calendar 2025 Q2
I wanted to come back to tariffs. I appreciate all the details. So you're dialing in the $60 million full year, $140 million previously
Show response
CFO clarified full year $75M vs $140M prior = $65M benefit, less $50M pulled price = net $15M, ~$10M flowed to guidance. Staying cautious with potential August 1 headwind.
Calendar 2024 Q4
how are you thinking about price as a contributor in those segments? And then maybe if you could parse out what's normal course of business price versus tariff related pricing
Show response
CFO confirmed 1.5-2% price includes $20M for China tariffs; Mexico/Canada tariff pricing would be additive if enacted.
of the incremental $80 million, how is that split between the two savings buckets?
Show response
Management explained 80/20 benefits will be captured in the same productivity column as Transformation rather than separated.
Show 5 more companies
DOVDover Corporation6 questions · 3 reporting periods · 0 of 6 challenging
Calendar 2025 Q2
first, any update on the $60 million? And then more broadly, did you remark the tariffs back to the higher rates?
Show response
Rich confirmed reshoring on track with additional pricing deployed post-Q2; no additional tariff headwind expected in H2; competitive advantage allows pricing in excess of costs where Dover leads.
Are there any specific segment drivers? Was it fairly broad-based?
Show response
Rich indicated July tracking indicates solid book-to-bill for Q3; broad-based rather than concentrated in specific segments.
Calendar 2025 Q1
if you were to strike the line today, how are you thinking about the net impact with all the hedges and everything in terms of the tailwind at today's rates?
Show response
Rich indicated current FX rates would roughly offset the guidance trim, the euro rallying over 5% vs dollar has turned headwind into tailwind.
in terms of what you've announced to the channel and customers, do you have all the price out there that you need to mitigate the tariffs for this year?
Show response
Rich confirmed vast majority of pricing is deployed but noted it's a moving target given tariff uncertainty; pricing just went out the prior night on one business. Realization lag exists.
Calendar 2024 Q4
how large has the total addressable market for Dover grown over the last couple of years? And where do you think your share of that can run?
Show response
Rich acknowledged TAM has grown significantly but candidly stated nobody can accurately size it yet; proud of management team's execution in complex situation.
any detail in the nature of the applications you're winning? And any concentration, is there 1 to 2 customers? Is it fairly broad-based?
Show response
Rich confirmed biopharma orders are broad-based, driven by end-use production pull-through after channel inventory cleared in first half of 2024.
PHParker Hannifin5 questions · 3 reporting periods · 1 of 5 challenging
Calendar 2025 Q4
Can you update us on what the annualized tariff expense that you absorbed. And as you progress through the mitigation measures, is it fair to think that as you get into the second half of calendar ...
Show response
Todd declined to quantify tariff expense or predict tariff trajectory. Pointed to record margins as evidence of successful mitigation. Would not commit to improved incrementals from tariff lapping. Emphasized managing whatever happens in real-time with transparency to customers.
Any early observations on confidence around cost synergies? And then as you've been mapping the combination, any early view on the sales synergy side?
Show response
Jenny expressed high confidence in $220M cost synergies by year 3, validated by plant visits during diligence. No revenue synergies modeled but sees upside from combined customer relationships and distribution networks. Integration team assembled on Parker side.
Calendar 2025 Q3
the adjusted op target was 27%. The top end of the guide this year is 27%. So basically got there 3 years early
Show response
Jenny noted margin is just one of 5 FY29 targets (growth, EPS, cash flow also matter). Guide reflects current visibility. Team accomplishment but not ready to reset the target.
Is this predominantly the MRO piece of that business? Or are you beginning to see a little bit of load-in from OEMs
Show response
Jenny confirmed construction recovery is both MRO and OEM sides, a positive signal for broadening demand.
Calendar 2025 Q1
I am surprised there hasn't been at least a smaller bolt-on type deal given you've been on your front foot
Show response
Jenny reiterated pipeline has assets of all sizes and it's a timing issue. Todd added capacity has never been greater with over $5B EBITDA and $3B cash flow, it's about finding the right strategic fit.
SWKStanley Black & Decker3 questions · 3 reporting periods · 1 of 3 challenging
Calendar 2026 Q2
cost or productivity actions that you had planned to take in 2Q that you might have shifted to future quarters
Show response
Linzey cited his own model showing an underlying shortfall; Hallinan rejected the premise and walked through the below-the-line and refund bridge.
Calendar 2026 Q1
I've always thought about that as really a 5 to 6-year churn, but curious what you see as a life cycle there
Show response
Nelson said 5-6 year replacement cycle more applicable to DIY; professionals replace faster due to high intensity of use and job-site outfitting. Pandemic pull-ahead effect believed to be behind them. Building out three core platforms (20V XR, FLEXVOLT, POWERSHIFT) with full trade-specific tool ecosystems.
Calendar 2024 Q4
Can you just dimension how much of the offsetting actions are price mitigation, versus the supply chain reconfiguration, and then maybe any color on this, the pricing assumption
Show response
Hallinan didn't break out exact split but indicated price first with supply chain following. Allan and Nelson added extensive color on the three-pronged tariff plan.
EMREmerson Electric2 questions · 2 reporting periods · 0 of 2 challenging
Calendar 2025 Q3
Is there any way you can sensitize the content per new reactor or anything you can add on the aftermarket side
Show response
Greenfield nuclear content approximately $40M per reactor plus $40M+ over 10-year MRO lifecycle. Scope includes control systems, instrumentation, and valves.
Calendar 2024 Q4
Any context you can offer on the elongation of the sales cycle there or when these wins might begin to convert to the order backlog?
Show response
New combined cycle plants are 5-6 year ventures. Modernization projects convert faster. Nuclear also longer cycle.
MMM3M Company2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2026 Q2
What portion is incremental share or TAM expansion versus replacing or cannibalizing existing SKUs?
Show response
Bill said ~75% of launches are incremental Class 3s and ~25% are Class 4/5 adjacencies, with the mix shifting toward 4s and 5s over time.
What's your current capacity utilization across the footprint?
Show response
Bill said utilization runs ~63.5-64% with upside, and network consolidation is a multi-year transformation opportunity.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| IEX IDEX Corporation | 11 | 0%none of 11 questions |
| HUBB Hubbell Incorporated | 10 | 0%none of 10 questions |
| LII Lennox International | 10 | 0%none of 10 questions |
| ALLE Allegion | 8 | 0%none of 8 questions |
| AME Ametek | 8 | 0%none of 8 questions |
| PNR Pentair | 7 | 14%1 of 7 questions |
| DOV Dover Corporation | 6 | 0%none of 6 questions |
| PH Parker Hannifin | 5 | 20%1 of 5 questions |
| SWK Stanley Black & Decker | 3 | 33%1 of 3 questions |
| EMR Emerson Electric | 2 | —Rate withheld: fewer than 3 questions |
- IEXIDEX Corporation · 11 questions0%none of 11 questions
- HUBBHubbell Incorporated · 10 questions0%none of 10 questions
- LIILennox International · 10 questions0%none of 10 questions
- ALLEAllegion · 8 questions0%none of 8 questions
- AMEAmetek · 8 questions0%none of 8 questions
- PNRPentair · 7 questions14%1 of 7 questions
- DOVDover Corporation · 6 questions0%none of 6 questions
- PHParker Hannifin · 5 questions20%1 of 5 questions
- SWKStanley Black & Decker · 3 questions33%1 of 3 questions
- EMREmerson Electric · 2 questions—rate withheld: under 3 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 15 | 0%none of 15 questions | 9 |
| 2025 Q1 | 12 | 8%1 of 12 questions | 7 |
| 2025 Q2 | 13 | 0%none of 13 questions | 7 |
| 2025 Q3 | 6 | 0%none of 6 questions | 4 |
| 2025 Q4 | 12 | 0%none of 12 questions | 6 |
| 2026 Q1 | 3 | 0%none of 3 questions | 2 |
| 2026 Q2 | 11 | 18%2 of 11 questions | 6 |
- 2024 Q415 questions · challenge rate 0% (none of 15 questions) · 9 companies
- 2025 Q112 questions · challenge rate 8% (1 of 12 questions) · 7 companies
- 2025 Q213 questions · challenge rate 0% (none of 13 questions) · 7 companies
- 2025 Q36 questions · challenge rate 0% (none of 6 questions) · 4 companies
- 2025 Q412 questions · challenge rate 0% (none of 12 questions) · 6 companies
- 2026 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2026 Q211 questions · challenge rate 18% (2 of 11 questions) · 6 companies
Topics
Topics tagged on this analyst’s questions.
- Demand28
- Trade Tariffs18
- Margin17
- Revenue Growth17
- Pricing13
- Capex Investment10
- Cost Pressure8
- Competitive Dynamics5
- Capital Allocation4
- M&A4
Show all 18 topics
- Inventory4
- Macroeconomic4
- Regulation Policy3
- Guidance Reliability3
- Innovation & R&D2
- Fx1
- Product Launch1
- Cloud & AI1